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Abstract
AIM
To assess the quality of and to critically synthesize the 
available data on hepatitis C infections in the Middle 
East and North Africa (MENA) region to map evidence 
gaps.
METHODS
We conducted an overview of systematic reviews 
(SRs) following an a priori developed protocol 
(CRD42017076736). Our overview followed the preferred 
reporting items for systematic reviews and meta-
analyses guidelines for reporting SRs and abstracts and 
did not receive any funding. Two independent reviewers 
systematically searched MEDLINE and conducted a 
multistage screening of the identified articles. Out of 
5758 identified articles, 37 SRs of hepatitis C virus (HCV) 
infection in populations living in 20 countries in the MENA 
region published between 2008 and 2016 were included 
in our overview. The nine primary outcomes of interest 
were HCV antibody (anti-) prevalences and incidences 
in different at-risk populations; the HCV viremic (RNA 
positive) rate in HCV-positive individuals; HCV viremic 
prevalence in the general population (GP); the prevalence 
of HCV co-infection with the hepatitis B virus, human 
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immunodeficiency virus, or schistosomiasis; the HCV 
genotype/subtype distribution; and the risk factors for 
HCV transmission. The conflicts of interest declared by 
the authors of the SRs were also extracted. Good quality 
outcomes reported by the SRs were defined as having 
the population, outcome, study time and setting defined 
as recommended by the PICOTS framework and a 
sample size > 100.
RESULTS
We included SRs reporting HCV outcomes with different 
levels of quality and precision. A substantial proportion of 
them synthesized data from mixed populations at differing 
levels of risk for acquiring HCV or at different HCV 
infection stages (recent and prior HCV transmissions). 
They also synthesized the data over long periods of time 
(e.g. , two decades). Anti-HCV prevalence in the GP varied 
widely in the MENA region from 0.1% (study dates not 
reported) in the United Arab Emirates to 2.1%-13.5% 
(2003-2006) in Pakistan and 14.7% (2008) in Egypt. 
Data were not identified for Bahrain, Jordan, or Palestine. 
Good quality estimates of anti-HCV prevalence in the GP 
were reported for Algeria, Djibouti, Egypt, Iraq, Morocco, 
Pakistan, Syria, Sudan, Tunisia, and Yemen. Anti-HCV 
incidence estimates in the GP were reported only for 
Egypt (0.8-6.8 per 1000 person-year, 1997-2003). In 
Egypt, Morocco, and the United Arab Emirates, viremic 
rates in anti-HCV-positive individuals from the GP were 
approximately 70%. In the GP, the viremic prevalence 
varied from 0.7% (2011) in Saudi Arabia to 5.8% 
(2007-2008) in Pakistan and 10.0% (2008) in Egypt. 
Anti-HCV prevalence was lower in blood donors than 
in the GP, ranging from 0.2% (1992-1993) in Algeria 
to 1.7% (2005) in Yemen. The reporting quality of 
the outcomes in blood donors was good in the MENA 
countries, except in Qatar where no time framework 
was reported for the outcome. Some countries had 
anti-HCV prevalence estimates for children, transfused 
patients, contacts of HCV-infected patients, prisoners, 
sex workers, and men who have sex with men.
CONCLUSION
A substantial proportion of the reported outcomes may 
not help policymakers to develop micro-elimination 
strategies with precise HCV infection prevention and 
treatment programs in the region, as nowcasting HCV 
epidemiology using these data is potentially difficult. 
In addition to providing accurate information on HCV 
epidemiology, outcomes should also demonstrate 
practical and clinical significance and relevance. Based 
on the available data, most countries in the region 
have low to moderate anti-HCV prevalence. To achieve 
HCV elimination by 2030, up-to-date, good quality data 
on HCV epidemiology are required for the GP and key 
populations such as people who inject drugs and men 
who have sex with men. 
Key words: Hepatitis C; Meta-research; Risk factors; 
Incidence; Genotype; Middle East and North Africa; 
Systematic review; Micro-elimination; Pakistan; Gulf 
Cooperation Council
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Core tip: To achieve hepatitis C virus (HCV) infection 
elimination goals by 2030, precise prevention strategies 
targeting specific populations at higher risk of acquiring 
HCV infection and treatment programs require the 
development of evidence-based health policies. HCV 
infection epidemiology in the countries of the Middle 
East and North Africa was characterized in 37 systematic 
reviews (SR) during the last decade. Our systematic 
overview critically analyzes and synthesizes the findings 
of these SRs to map the evidence gaps in the region. 
Additionally, we assessed the quality of the reported 
outcomes and documented conflicts of interest of the 
SR authors who disclosed financial relationships with 
pharmaceuticals.
Chaabna K, Cheema S, Abraham A, Alrouh H, Lowenfels AB, 
Maisonneuve P, Mamtani R. Systematic overview of hepatitis 
C infection in the Middle East and North Africa. World J 
Gastroenterol 2018; 24(27): 3038-3054  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v24/i27/3038.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v24.i27.3038
INTRODUCTION
In 2017, the World Health Organization estimated that 
71 million people suffer from chronic hepatitis C virus 
(HCV) infection worldwide[1]. In 2015, HCV infection 
resulted in 399000 deaths[1], predominantly from 
complications such as liver cirrhosis and hepatocellular 
carcinoma (HCC)[1,2]. Egypt had the largest iatrogenic 
transmission of blood-borne pathogens in the general 
population (GP) worldwide[3]. The use of parenteral 
anti-schistosomiasis therapy in Egypt, extensively 
practiced with poor sterile techniques since the 1920s, 
is considered to be the leading cause of the dramatic 
increase in the human HCV reservoir in the GP[3]. In 
Egypt, HCV antibody (anti-) prevalence was estimated 
to be 15% in 2008[4] and 6% in 2014[5]. Globally, 
Pakistan has the second largest number of people with 
viremic HCV infection, after China[6]. Due to the high 
burden of HCV infection in Egypt and Pakistan, the 
MENA region has been identified as the region most 
affected region by HCV worldwide.
Our primary objective was to assess the quality of 
the data reported by the published systematic reviews 
(SRs) of HCV epidemiology in MENA countries taking 
into account conflict of interest disclosed by the authors 
of these SRs. Secondarily, we aimed to critically analyze 
all data reported by the SRs to map evidence gaps and 
to report a comprehensive synthesis. 
MATERIALS AND METHODS
We conducted an overview of SRs based on the Cochrane 
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Handbook for Systematic Reviews of Interventions[7]. 
This overview is part of the Population Health 
Publications Assessment Project that aims to assess the 
methodological quality of published SRs on population 
health issues in the MENA region. The ultimate goal of 
this meta-research (i.e., research on research[8]) is to 
evaluate and contribute to the improvement of population 
health research practices in the MENA region[9]. 
An a priori protocol was registered with the 
International Prospective Register of Systematic Reviews 
(PROSPERO registration number CRD42017076736)[10]. 
We report this overview according to the standards 
set out in the preferred reporting items for syste-
matic reviews and meta-analyses (PRISMA) 2009 
guidelines[11-13]. PRISMA checklists for SRs[11,12] and 
abstracts[13] are reported as Supplementary Materials 1 
and 2, respectively. We also assessed the methodological 
quality of our overview using the Assessment of Multiple 
Systematic Reviews (AMSTAR) tool[14]. The AMSTAR 
checklist is provided as Supplementary Material 3.
Inclusion and exclusion criteria
We included all SRs (publication date: January 2008 to 
December 2016) of HCV infection related to the countries 
in the MENA region published in peer-reviewed journals 
since 2008, the publication year of the first version 
of the Cochrane Handbook for Systematic Reviews of 
Interventions[7]. We included MENA countries where 
Arabic, English, French, and/or Urdu are the primary 
official languages and/or the medium of instruction in the 
colleges/universities. These languages are those spoken 
by the authors of this overview.
Population of interest
Our population of interest was the population living in 
the following 20 countries: Algeria, Bahrain, Djibouti, 
Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, 
Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Sudan, 
Syria, Tunisia, the United Arab Emirates (UAE), and 
Yemen. These selected MENA countries have a combined 
population of over 560 million people, accounting for 
approximately 8% of the world’s population[15]. We 
excluded SRs of HCV infection in populations from 
countries outside the MENA region and SRs with military 
personnel who were based in the MENA region but not 
from the region.
Primary outcomes
We extracted the following variables: Anti-HCV 
prevalence and incidence in different at-risk populations, 
HCV viremic rates in HCV positive individuals, and HCV 
viremic prevalence in the GP. Viremic infection represents 
the presence of HCV in the bloodstream detected 
with polymerase chain reaction (HCV RNA-positive). 
We also extracted the prevalence of co-infection with 
HBV (hepatitis B surface antigen, HBsAg), human 
immunodeficiency virus (HIV), or schistosomiasis; HCV 
genotype/subtype distributions; and risk factors for 
HCV transmission. Additionally, we extracted conflicts of 
interest reported by the SR authors.
Literature search and data management
Two reviewers (AA and HA) independently and 
systematically searched the Medical Literature Analysis 
and Retrieval System Online (MEDLINE) through the 
search engine PubMed[16] using broad search criteria 
(Supplementary Material 4). The search criteria, 
limited to reviews, systematic reviews, and meta-
analysis, identified 5758 reviews (Figure 1). After 
removing duplicate publications of the same reviews 
with Endnote[17], title/abstract screening and then full-
text screening were conducted by AA and HA with 
Rayyan software[18,19]. Discrepant inclusions of SRs were 
discussed by AA, HA, and KC under the supervision of the 
senior authors. We eventually included 37 SRs of HCV 
infection in MENA countries (Figure 1). The characteristics 
of these included SRs are described in Supplementary 
Material 5. Data extraction was conducted by AA and KC 
and crosschecked for accuracy. 
Conflicts of interest
We recorded the conflicts of interest reported by the SR 
authors who disclosed financial relationships. An asterisk 
(*) was inserted next to the outcomes reported by SRs 
with at least one author who disclosed direct or indirect 
financial relationships with Gilead Science, AbbVie, 
Merck, Bristol-Myers Squibb, or Janssen Therapeutics. 
In 2013, Gilead Science launched sofosbuvir-based 
regimens to cure chronic infections with HCV genotypes 
1, 2, 3, and 4[20] (viremic cases) that made elimination 
of HCV infection achievable for the first time. A large 
proportion of patients (> 90%) treated with sofosbuvir 
associated with another direct-acting antiviral drug (DAA) 
demonstrated a sustained virological response[21]. The 
recommended regimens and treatment durations differ 
according to the HCV genotype infection. Additionally, 
sofosbuvir-based regimens appear to be relatively safe[21]. 
However, cases of cardiac events have been reported 
when sofosbuvir-based treatments were administered in 
combination with amiodarone and/or propranolol[22,23]. 
Since then, new DAAs have been developed by other 
pharmaceuticals (AbbVie, Merck, Bristol-Myers Squibb, 
and Janssen Therapeutics)[24].
Quality assessment and conflict of interest
Good quality outcomes reported by the SRs were defined 
as having the population, outcome, timing, and setting 
defined as recommended by the PICOTS framework[25,26] 
(intervention and comparator being irrelevant in our 
overview) and a sample size > 100[27]. A maximum score 
of six was given to the outcome if the following measures 
were included: (1) Population profile, such as pregnant 
women and patients under hemodialysis; (2) the method 
used for the outcome estimation, such as meta-analysis 
or weighted average; (3) the data collection period; (4) 
the study geographic location; (5) the number of studies; 
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sexually transmitted infections; healthcare workers; 
barbers; contacts of HCV-infected patients; people who 
inject drugs (PWID); prisoners; sex workers; and men 
who have sex with men (MSM) (Tables 1-3). We took 
financial disclosures into account when assessing and 
reporting these outcomes[31]. Whenever two outcomes 
describing the same population in the same country 
had the same quality score, we reported the outcome 
extracted from the SR the authors of which disclosed 
no financial relationship with HCV DAA pharmaceutical 
companies.
RESULTS
Quality assessment - PICOTS framework
Only six out of 37 SRs of HCV epidemiology in the 
MENA region published after 2008 conducted a quality 
assessment of the studies included[6,27,32-35]. HCV 
prevalence or incidence is meaningful only when the 
population, the outcome, the study setting, and the study 
period are stated (PICOTS framework)[25]. Additionally, for 
SRs, reporting the quantitative synthesis method used 
and the number of studies included in the synthesis as 
recommended by PRISMA guidelines[11-13] is critical to 
enable the assessment of the quality of the outcome (Tables 
1-3). Some SRs failed to precisely report the methodology 
they used for their quantitative synthesis[36-38]. 
In addition to providing a time framework for mor-
bidity measurements, reporting the collection period 
for HCV prevalence is essential because changes in 
and (6) a total sample size > 100. 
Synthesis 
We narratively synthesized the data on HCV infection in 
each of the 20 MENA countries in at-risk populations. 
We defined the GP as individuals from the community 
who are not in any specific population category such 
as blood donors or outpatients. More specifically, we 
reported HCV epidemiology in the GP separately from 
that in blood donors. Blood donors are selected healthy 
populations that may not be representative of the 
GP[28,29]. Therefore, if a SR reported an outcome for the 
GP including specific population categories, we reported 
this GP specifying all the included population categories.
Extracted data from the included SRs were compiled 
into evidence tables. We reported anti-HCV prevalence 
in at-risk populations from the SRs and the quality 
assessment of the reported prevalence (Supplementary 
Materials 6 and 7). Country-level anti-HCV prevalence 
was classified into low (< 1.5%), moderate (1.5%-3.5%), 
and high (> 3.5%) levels[30]. If available, we also 
reported the viremic rate in anti-HCV positive individuals 
and the viremic prevalence in the GP. 
For each country, we mapped evidence gaps with 
the most up-to-date anti-HCV prevalence with the best 
quality assessment (highest quality assessment score) 
in the GP; blood donors; pregnant women; children; 
patients on dialysis; hemophiliac, thalassemic, and 
transfused patients; patients with HCC, acute liver 
disease, chronic liver disease (CLD), HIV and/or other 
Records identified through 
database searching
(n  = 5758)
Additional records identified 
through other sources
(not applicable)
Records after duplicates removed
(n  = 11)
Records screened
(n  = 5747)
Records excluded1
(n  = 5086)
Full-text articles assessed 
for eligibility
(n  = 661)
Full-text articles excluded, 
with reasons2
(n  = 624)
Systematic reviews included 
in qualitative synthesis
(n  = 37)
Systematic reviews included in 
quantitative synthesis (meta-analysis)
(Not applicable)
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Figure 1  PRISMA 2009 Flow diagram describing the selection of the systematic reviews reporting hepatitis C outcomes in our systematic overview. 
Reasons of exclusion: 1Systematic reviews were excluded from the overview because they did not meet our inclusion criteria; 2Not a systematic review (n = 116), no 
hepatitis C outcomes (n = 472), not a polulation from MENA (n = 34), duplicate (n = 1), and publication in Portuguese (n = 1).
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risk factors for HCV were demonstrated over time 
in Egypt and other countries[39]. Out of the 29 SRs 
reporting the anti-HCV prevalence, 16 (55%) failed to 
accurately report the years during which data collection 
occurred[32,34,36-38,40-50]. Thirteen SRs did not report the 
data collection years at all[34,36-38,40-48], two reported the 
publication year as or instead of the data collection period 
of the study[32,49], and one SR published in 2011 stated 
“unless indicated the estimates were for 2004 because 
of lack of more recent data”[50]. The choice of this year, 
i.e., 2004, was not justified and appears arbitrary. For 
instance, the authors reported an anti-HCV prevalence 
in individuals with sexually transmitted diseases (STD) 
in Saudi Arabia of 15.9%* in 2004, as no year was 
indicated[50]. Remarkably, the actual study that estimated 
the prevalence in individuals with STDs in Saudi 
Arabia reported 1990 as the year of data collection[51]. 
Additionally, we identified SRs pooling the prevalence 
measured over a long time period such as a pooled 
estimate for 1982-2010 in Tunisia[52] or for 1989-2012 
in Sudan[27]. These estimates that encompass long time 
periods do not reflect changes in prevalence over time 
and do not accurately describe the past and current HCV 
epidemiology in a population. 
Similarly, for genotype distribution, only two[50,53] 
of the 18 SRs[6,27,33,37,38,40,43-45,48-50,53-58] reported HCV 
genotype/subtype distributions, and one[50] of the 12 
SRs[27,39,40,44,45,50,52,53,57,59-61] reported risk factors with 
the data collection year provided, which would be an 
indicator if changes in genotype/subtype geographical 
distributions or in risk factors occurred over time. However, 
regarding incidence, six SRs[33,48,50,52,59,61] identified data 
points, and all of them reported the data collection years 
as those provided by the included studies.
Regarding the definitions of populations, we 
identified SRs pooling anti-HCV prevalences from 
populations at differing risk levels for acquiring HCV 
infections[27,33,37,41,52,59,62,63]. We question the meaningfulness 
of these estimated outcomes for mixed populations. How 
would clinicians and policymakers interpret and use an 
estimated anti-HCV prevalence for a mixed population 
including, for instance, patients with lymphoproliferative 
disorders, prisoners, patients with depression, mothers, 
and sex workers[41]? Regarding the GP, we identified 
SRs that combined blood donors with the GP[27,33,52,59,62]. 
Healthy blood donors (voluntary and non-remunerated) 
Table 1  Hepatitis C antibody prevalence evidence gap mapping with quality assessment, North Africa and Pakistan
Algeria Djibouti Egypt Libya Morocco Sudan Tunisia Pakistan
Blood donors 0.2% 
(1992-1993)1
0.3% 
(1998-2000)1
1.7%-16.8% 
(2006-2009)1
0.9%-6.6% 
(1992-2001)1
0.2%-0.8% 
(2005-2011)1
0.0%-1.3% 
(2005-2007)1
0.1%-0.9% 
(2000-2010)1
0.2%-8.6% 
(2000-2006)1
Pregnant women 0.6% (2008)1 No data 8.6%-12.7% 
(-)3
0.4%-2.3% (-)3 1.0% (-)2 0.6% (2006)1 0.2% (2006)1 5.3% 
(2001-2006)1
Children No data No data 2.1%-5.8% 
(2002-2005)1
No data No data No data No data 1.7% (-)2
Hemodialysis, renal dialysis, 
and/or dialysis patients
39.0% (-)3 No data 46.1%-100% 
(2002-2009)1
32.3% 
(2009-2010)1
54.1%-68.3% 
(2003-2004)1
8.5%-23.7% 
(2005-2010)1
14.6%-32.6% 
(2000-2002)1
38.8% 
(2003-2005)1
Hemophiliac or other 
bleeding disorder patients
30.0% 
(2010-2011)2
No data No data No data 2.3%-42.4% 
(1981-2006)1
13.0% (2008)2 55.7% (-)2 25.0%-56.0% 
(2000-2002)1
Transfused patients No data No data 11.1%-81.6% 
(2000-2008)1
10.8% 
(1999-2001)1
No data No data 4.7% 
(2008-2009)1
13.2%-15.4% 
(2002)1
Thalassemic patients No data No data 19.5%-69.6% 
(2000-2010)1
No data 68.3%-76.0% 
(-)3
No data 6.1% (-)2 36.2-56.8% 
(1999-2003)1
Patients with hepatocellular 
carcinoma
No data No data 85.9% 
(1997-2004)1
No data 57.3% 
(2003-2006)2
11.0% 
(1996-1998)1
19.0%-63.5% 
(1982-< 1995)2
53.7% (-)2
Patients with acute liver 
disease
No data No data No data No data 0.0% (1999)1 6.3% (2007)2 8.0%-48.0% 
(< 1995)3
No data
Patients with chronic liver 
disease
No data No data No data No data 73.7% 
(1983-1986)2
No data 80.5% 
(2005-2008)2
0.0%-86.6% 
(2000-2005)1
Healthcare workers No data No data No data 2.0%-6.8% 
(1992-2001)1
No data 0.0% 
(2005-2007)1
1.0% (2005)1 5.6%-6.0% 
(2001-2002)1
Barbers No data No data 12.3% (-)3 No data 1.1%-5.0% 
(2001-2007)1
No data No data No data
Contact of patients with 
hepatitis C
No data No data No data No data No data No data No data 4.3%-38.0% 
(2000-2004)1
People who inject drugs No data No data 63.0% (-)2 94.2% (2010)1 22.9%-79.2% 
(2010-2012)1
No data 21.7%-29.1% 
(2009-2012)1
57.0% (-)2
Prisoners No data No data No data 23.7% (2006)1 No data No data No data No data
Patients with HIV and/or 
other sexually transmitted 
infection
No data No data No data 44.9%-54.1% 
(2003)1
5.4% 
(2006-2010)1
1.7% 
(2010-2012)1
35.5% 
(1997-2006)1
No data
Sex workers No data No data No data 5.2%-7.3% 
(2010-2011)1
No data 0.0%-5.1% 
(2011-2012)1
1.1% (2007)1 No data
Men who have sex with men No data No data No data No data No data 0.0%-5.9% 
(2011-2012)1
No data No data
Prevalence, year of data collection. 1Good quality; 2Average quality; 3Poor quality.
Chaabna K et al . HCV in the MENA region
3043 July 21, 2018|Volume 24|Issue 27|WJG|www.wjgnet.com
recruited with selection programs likely have lower 
anti-HCV prevalence than the GP[64]. Hence, in SRs 
pooling blood donor estimates with the GP estimates, 
the pooled estimates likely underestimate the actual 
anti-HCV prevalence in the GP. Furthermore, as meta-
analyses give greater weight to studies with higher 
sample sizes and the sample sizes of studies describing 
anti-HCV prevalence in blood donors are often large, 
these pooled anti-HCV prevalences are more likely to 
be underestimated. In a country such as Djibouti where 
there were no identified studies reporting in the GP and 
only one identified study reporting on blood donors, 
reporting the estimate in blood donors as the lower limit 
of possible anti-HCV prevalence in the GP[6] might be 
relevant because of the scarcity of data. Riou et al[35] 
used that estimate to provide an adjusted estimate for 
the GP. We believe that in countries where data points 
among the GP are available, blood donors should be 
excluded.
Similarly, for reported genotype/subtype distributions 
and risk factors, mixing populations limited the ability to 
analyze that data in-depth. 
Conflict of interest
Out of the 37 SRs included in our overview, 32 SRs 
had authors who disclosed no conflict of interest. In 
one SR[65], authors disclosed financial support from a 
US National Science Foundation Graduate Research 
Fellowship, a Sigma Xi Grant-in-Aid of Research, and 
the Global Health Program at the University of Michigan 
School of Public Health. Four SRs[6,34,50,56] reported 
at least one author who disclosed a direct or indirect 
financial relationship with pharmaceutical companies; 
among these SRs, three reported financial support from 
HCV DAA pharmaceutical companies[6,50,56]. Gower et al[6] 
reported indirect financial support from Gilead Science, 
Table 2  Hepatitis C antibody prevalence evidence gap mapping with quality assessment, Arab Peninsula
Bahrain Kuwait Oman Qatar Saudi Arabia United Arab 
Emirates
Yemen
Blood donors No data 0.8%-1.2% 
(nationals) 
(2002) 
5.4%-13.5% 
(migrants) 
(2002)1
0.4%-0.7% 
(2006-2011)1
1.1% (nationals and 
migrants) 0.5%(nationals) 
(-)2
0.0%-5.6% (nationals 
and migrants, 1988-2009) 
0.4%-4.2% (nationals, 
1990-2009) 0.0%-34.0% 
(migrant, 1990-2002)1
0.5%-1.1% 
(2004-2009)1
1.7% (2005)1
Pregnant women No data No data No data No data 0.1%-4.6% (1989-2002)1 13.0%-13.4% 
(migrants) 
(1994-1996)1
3.3%-8.5% 
(2011)1
Children No data No data No data No data 0.7%-1.8% (1989-2002)1 No data 2.1% 
(2007-2009)1
Hemodialysis, renal 
dialysis, and/or 
dialysis patients
9.2% (-)3 27.0%-71.0% 
(1992-1995)1
26.5% (1991)1 44.6% (-)2 14.7%-78.2% (1995-2008)1 24.4% 
(1991-1993)1
40.0%-62.7% 
(1997-2013)1
Hemophiliac or other 
bleeding disorder 
patients
60.0% (1992)2 No data No data No data 78.6% (-)3 No data No data
Transfused patients No data No data No data No data 4.6%-78.6% (1990-2011)1 No data No data
Thalassemic patients No data 33.0% 
(1965-1995)1
No data No data 12.7%-70.0% (1990-2000)1 18.8% 
(1990-2001)2
No data
Patients with 
hepatocellular 
carcinoma
No data No data No data No data 48.5% (2006-2008)1 No data 28.4%-38.2% 
(2001-2010)1
Patients with acute 
liver disease
No data No data No data No data 3.4%-40.7% (2000-2005)1 1.2% 
(2006-2007)1
6.4%-8.8% 
(1997-1999)1
Patients with chronic 
liver disease
No data 37.8% (-)2 No data 29.4 (2000-2005)1 11.9%-65.0% (1989-2004)1 43.7% (-)2 33.8% (-)3
Healthcare workers No data 0.9% (-)2 0.0% (-)2 No data 0.0%-0.3% (2001-2005)1 No data 1.1%-3.5% (-)3
Barbers No data No data No data No data No data No data No data
Contact of patients 
with hepatitis C
No data No data No data No data 0.0%-1.6% (-)2 27.0% 
(1994-1996)1
No data
People who inject 
drugs
No data No data 48.1% (2011)1 No data 14.4%-54.7% (1995-2004)1 No data No data
Prisoners No data No data No data No data No data No data No data
Patients with HIV 
and/or other sexually 
transmitted infection
No data 0.9%(2012)1 No data No data 12.0%-15.9% (1985-2010)1 No data No data
Sex workers No data No data No data No data No data No data No data
Men who have sex 
with men
No data No data No data No data No data No data No data
Prevalence, year of data collection. 1Good quality; 2Average quality; 3Poor quality.
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AbbVie, and Bristol-Myers Squibb. Bruggmann et al[56] 
and Sievert et al[50] reported financial support from 
Gilead Science, AbbVie, Merck, Bristol-Myers Squibb, 
and Janssen Therapeutics. Bruggmann et al[56] had 34 
authors who disclosed direct or indirect financial relation-
ships with at least one of the HCV DAA pharmaceutical 
companies (37% of the total number of authors). 
Furthermore, six authors did not disclose their conflict 
of interest. In Sievert et al[50], out of the 29 authors, 13 
(45% of the total number of authors) disclosed direct 
or indirect financial relationships with at least one of the 
HCV DAA pharmaceuticals.
Interestingly, two[6,56] of the three SRs that reported 
financial support from HCV DAA pharmaceutical 
companies were published in 2014 and were the only 
ones that estimated the total number of viremic cases 
in the GP. They were also the only SRs that estimated 
the genotype/subtype distributions in the GP of the 
MENA region, except for Morocco[43], Pakistan[50,55], and 
Tunisia[43] where the distributions were also computed 
by a couple of additional SRs. In Saudi Arabia, the third 
SR estimating genotype/subtype distributions also 
had authors who disclosed financial relationships with 
HCV DAA pharmaceutical companies[50]. Remarkably, 
in both SRs[6,56], the authors did not follow the PRISMA 
guidelines (2009)[11] for reporting their reviews in detail; 
thus, we question the replicability of the reviews. Flow 
diagrams depicting the numbers of records identified, 
included, excluded, and, most importantly, the reasons 
for the exclusions were not presented in those SRs[6,56]. 
Bruggmann et al[56] did not report the search criteria, 
eligibility criteria, or the risk of bias assessment of 
the included studies. Additionally, Bruggmann et al[56] 
reported that an expert panel reviewed the findings and 
analysis, and Gower et al[6] reported including “personal 
communication with experts within countries”. However, 
the authors did not report how they defined “expert” 
or any conflicts of interest of these experts[6,56]. These 
reviews[6,56] had been cited 185[56] and 890[6] times, 
respectively, by February 12, 2018 (Google Scholar 
citations) and published in journals with impact factors of 
3.9 and 11.3 (in 2014), respectively.
HCV prevalence
In the GP, the estimations of the most up-to-date anti-
HCV prevalence with the best quality ranged widely 
across MENA countries (Figure 2 and Tables 1-3). 
We identified low prevalence (< 1.5%) in Djibouti, 
Kuwait, Oman, Qatar, and UAE; moderate prevalence 
(1.5%-3.5%) in Algeria, Iraq, Lebanon, Libya, Morocco, 
Saudi Arabia, Sudan, Syria, and Tunisia; and high 
prevalence (> 3.5%) in Egypt, Pakistan, and Yemen. 
In Pakistan, anti-HCV prevalence may have increased 
from 5.4% in 1996-2007[62] to 6.7%* in 2007-2008[6]. 
No reported data in the GP was identified for Bahrain, 
Jordan, or Palestine. 
Table 3  Hepatitis C antibody prevalence evidence gap mapping with quality assessment, Fertile Crescent region
Iraq Jordan Lebanon Palestine Syria
General population 0.0%-4.0 % (2004-2012)1 No data 0.6%-2.9% (-)2 No data 2.8% (2004)1
Blood donors 0.2%-2.8% (2003-2013)1 0.1%-0.9% (2003-2011)1 0.0%-3.4% (< 2003)1 0.2%-0.3% (2003-2013)1 0.4% (2000-2011)1
Pregnant women 0.0%-5.1% (2004-2010)1 No data No data No data No data
Children 0.0% (2007-2009)1 No data No data No data No data
Hemodialysis, renal 
dialysis, and/or dialysis 
patients
4.9%-42.6% (2002-2011)1 21.0%-49.8% 
(2003-2008)1
16.0%-27.0% (-)2 17.9%-27.4% 
(2007-2013)1
21.0% (2006)1
Hemophiliac or other 
bleeding disorder patients
6.7%-40.3% (2006-2012)1 No data 10.0% (-)3 No data 20.5% (2007-2011)1
Transfused patients 3.4%-4.5% (2004-2008)1 No data No data No data 13.3% (2000)2
Thalassemic patients 4.0%-46.0% (2003-2012)1 32.8% (2008)1 0.0%-14.0% (> 1999)1 No data No data
Patients with 
hepatocellular carcinoma
26.1% (2000-2003)2 No data 19.6% (1998-2003)2 No data No data
Patients with acute liver 
disease
0.0%-71.9% (2007-2011)1 No data No data No data 1.0%(1995-1998)1
Patients with chronic liver 
disease
3.8%-62.0% (2005-2009)1 No data No data No data No data
Healthcare workers 0.0%-9.1% (2002-2010)1 0.7% (1999)1 0.4% (1999)1 No data 3.0%-3.8% (-)2
Barbers 0.3% (1999-2001)1 No data No data No data No data
Contact of patients with 
hepatitis C
1.2%-1.4% (1996-2001)1 No data No data No data No data
People who inject drugs No data No data 52.8% (2007-2008)1 45.2% (2010)1 60.5% (-)3
Prisoners 0.6% (1996-2001)1 No data 3.4% (-)3 No data No data
Patients with HIV and/or 
other sexually transmitted 
infection
1.2% (-)2 No data 7.7% (-)3 No data No data
Sex workers No data No data 0.0% (2007-2008)1 No data 2.0% (-)2
Men who have sex with 
men
No data No data 0.0% (2007-2008)1 No data No data
Prevalence, year of data collection. 1Good quality; 2Average quality; 3Poor quality.
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Summary points pertaining to the estimated anti-
HCV prevalences in blood donors, pregnant women, 
children, and patients with acute liver disease or CLD 
and HCC are highlighted in Supplementary Materials 8.
We identified that HCV transmission most likely 
occurs in healthcare settings. In all 20 MENA countries, 
patients with blood disorders such as hemophilia 
and thalassemia, patients undergoing hemodialysis, 
and patients who received transfusions had higher 
prevalences of anti-HCV than the prevalence in the GP. 
This suggests that transfusion-associated HCV infection 
may have occurred in these patients (Supplementary 
Material 8). Additionally, anti-HCV prevalences in 
healthcare workers in Iraq, Libya, and Syria suggest 
that in these countries, HCV transmission may also be 
due to occupational exposure (Supplementary Material 
8). Community-acquired HCV infection may also occur 
in the MENA countries; however, we identified evidence 
gaps in the region (Supplementary Material 8).
Anti-HCV prevalence measures were not often 
identified for key populations such as PWID, prisoners, 
and MSM. Anti-HCV prevalence data were predominantly 
missing for the countries of the Arab Peninsula. No 
reported data were identified for MSM, prisoners, or sex 
workers in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, 
the UAE, or Yemen. For PWID, anti-HCV prevalence 
data were identified in Egypt, Lebanon, Libya, Morocco, 
Oman, Pakistan, Palestine, Saudi Arabia, Syria, and 
Tunisia. For prisoners, reported anti-HCV prevalence data 
were identified in Iraq, Lebanon, and Libya.
Sexual transmission may also be a cause of HCV 
infection in some MENA countries. Anti-HCV prevalence 
data in patients with HIV or other STDs were missing 
for Algeria, Bahrain, Djibouti, Egypt, Jordan, Oman, 
Pakistan, Palestine, Qatar, Syria, the UAE, and Yemen. 
Anti-HCV prevalences in sex workers were reported for 
a few countries. 
HCV incidence
The incidence rate reflects the status of HCV transmission 
in a population. Nevertheless, up-to-date incidence data 
in MENA countries were lacking (Tables 4 and 5). In the 
GP, the anti-HCV incidence rate was reported only in 
Egypt, at 0.8-6.8 per 1000 person-year in 1997-2003. 
The incidence rate was the highest in patients undergoing 
hemodialysis in the UAE, at 108 per 1000 person-year in 
2003-2004. The incidence rates in patients undergoing 
hemodialysis were reported for Iraq, Jordan, Morocco, 
Tunisia, and the UAE. These findings suggest ongoing 
HCV transmission within healthcare settings in these 
countries.
Viremic rate
In the GP, the HCV viremic rate among anti-HCV 
positive individuals was 51.6%* (2011) in Saudi 
Arabia[6]; approximatively 70%* in Egypt (2008)[6], 
Morocco (2005-2011)[6], and the UAE (study dates not 
reported)[6]; 80.0%* (2012) in Tunisia[6]; and 87.4%* 
(2007-2008) in Pakistan[6]. Country-level HCV viremic 
prevalences ranged between 0.7%* [95% confidence 
interval (CI): 0.3%-3.8%, 2011][6] in Saudi Arabia and 
10.0%* (CI: 7.0%-12.2%, 2008)[6] in Egypt. The viremic 
prevalence was 1.1%* (0.4%-1.4%, 2005-2011)[6] in 
Morocco, 1.0%* (0.2%-2.0%, 2012)[52] in Tunisia, and 
5.8%* (1.4%-8.7%, 2007-2008)[6] in Pakistan. In anti-
HCV positive blood donors, the viremic rate was 60.0% 
in Libya (1992-2001)[52] and 20.0% in Saudi Arabia 
(1988-2009)[59]. In healthcare workers, the viremic 
rate was reported in Libya as 69.2% (1992-2004)[52]. 
In dialysis patients, the HCV viremic rate was 51.0% 
in Tunisia before 2000[52] and 60.5%-93.3% in 
2000-2003[52]; in Libya, it was 72.0% (before 2001)[52]. 
In HIV-infected patients in Morocco, the viremic rate was 
reported as 70.4% (study dates not reported)[49].
Co-infection with hepatitis B virus, HIV, or 
schistosomiasis
We identified two SRs[36,47] that reported HBV (HBsAg) 
and anti-HCV co-infection prevalence estimates; these 
estimates were only in HCC patients, and neither of 
Figure 2  Hepatitis C antibody prevalence evidence gap mapping with quality assessment, general population, MENA. MENA: Middle East and North Africa.
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these SRs[36,47] reported study dates/years. In Egypt, 
Pakistan, Saudi Arabia, and Tunisia, the anti-HCV 
prevalence was higher than the HBsAg prevalence, 
while the opposite finding was observed in Lebanon, 
Sudan, and Yemen (Supplementary Materials 9).
In Libya, 90.1% (CI: 78.2%-100%) of HIV-infected 
prisoners had an HCV co-infection (study dates not 
reported)[49]. In HIV-infected children, the prevalence 
of HCV co-infection was 43.0%-46.0% (1998-1999)[52]. 
The most up-to-date estimates of HCV co-infection 
in HIV-infected patients were 5.4% (2006-2010) in 
Morocco[52], 1.7% (CI: 0.2%-2.3%, study date not 
reported) in Sudan[27], 33.5% (CI: 20.4%-46.6%, 
1997-2005) in Tunisia[49,52], and 7.7% (study dates not 
reported) in Lebanon[33].
Studies on schistosomiasis and HCV co-infection 
were reported for Egypt[45,61], Sudan[27,45,46], and Saudi 
Arabia[59]. In Egypt, 7.7%-84.0% (2002-2011) of the 
schistosomiasis patients were also infected by HCV[61]. 
Prior to 2000, HCV prevalence in schistosomiasis 
patients was 16.3%-42.5%[61]. In Sudan, the prevalence 
of schistosomiasis and HCV co-infection ranged from 
4.5%[27] to 31.0% in 2001[27]. In Saudi Arabia, 17.9% of 
schistosomiasis patients were also infected with HCV[59].
HCV genotype and subtype
In the GP, genotype 1 was the most common genotype 
in Algeria (69.2%*)[6], Morocco (75.9%)[6,43], Tunisia 
(84.0%)[6,43], and Jordan (73.3%*)[6], while in Pakistan the 
most common genotype was genotype 3 (67.5%-86.7%)[40]. 
No data in the GP was reported for Bahrain, Djibouti, 
Oman, Qatar, or Yemen. In the other MENA countries it 
was genotype 4 (45.2*-93.1%*)[6,43,50,54,56] (Supplementary 
Materials 10 and 11). Interestingly, in Jordan, systematic 
reviews reporting genotype 4 as the most common 
genotype in the country had pooled estimates from 
the GP and other at-risk populations. In Morocco and 
Tunisia, subtype 1b was the most common genotype in 
the GP[43], while in Pakistan[50,55] and Saudi Arabia[50], it 
was 3a. In pregnant women, genotype 4 was reported 
as the most common genotype in Algeria, Egypt, Iraq, 
Libya, Saudi Arabia, Sudan, Tunisia, and Yemen[44], 
whereas genotype 1 was the most common genotype 
in Morocco[44]. Genotype distributions in blood donors[38] 
and in clinical populations, such as patients with CLD, 
non-Hodgkin lymphoma, thalassemia, or hemophilia, 
were similar to the distributions identified in the 
general population[38,57]. However, in PWID in Saudi 
Arabia, genotype 1 was reported as the most common 
genotype (48%), followed by genotype 3 (36.0%*)[50], 
whereas in Lebanon, genotype 3 was the most common 
genotype (26.3%-57.0%), followed by genotype 1 
(21.0%-42.1%) and genotype 4 (18.0-34.6)[38].
Risk factors associated with HCV infection
The risk factors for acquiring an HCV infection reported 
for MENA countries were factors associated with medical 
practices (blood transfusion, catheter use, hemodialysis, 
nosocomial exposure, and invasive procedures, among 
others)[27,39,40,44,45,50,52,53,57,59-61] (Supplementary Material 12). 
Table 4  Hepatitis C antibody incidence and/or seroconversion risk rate relative to the total sample size, and evidence gap mapping, 
Middle East and North Africa
Country Systematic review
Literature search 
period
Number 
of studies 
identified
Number of 
subjects
Population 
type
Estimation 
time period
HCV incidence 
rate (per 1000 
person-year)
Loss of 
follow-up
HCV sero-
conversion risk 
(%)
Duration of 
follow-up
Algeria
Fadlalla, 
2015[52]
1980-Unknown 0 0
Libya
Fadlalla, 
2015[52]
1980-Unknown 0 0
Morocco
Fadlalla, 
2015[52]
1980-Unknown 1 303
Hemodialysis 
patients
2003-2004 97 - - -
Tunisia
Fadlalla, 
2015[52]
1980-Unknown 1 276
Hemodialysis 
patients
2000-2002 28 - - -
Djibouti
Chaabna, 
2016[27]
Inception-2015 0 0
Sudan
Chaabna, 
2016[27]
Inception-2015 0 0
Egypt
Hussein, 
2016[48] 
Inception-
Unknown
- - - - 6.9 - - -
Mohamoud, 
2013[61]
Inception-
Unknown
2 2852
Children of 
villages with 
high HCV 
prevalence
2000-2006 2.7 - - -
Mohamoud, 
2013[61]
Inception-
Unknown
3 10318
General 
population
1997-2003 0.8-6.8 - - -
Mohamoud, 
2013[61]
Inception-
Unknown
1 2177
Pregnant 
women
1997-2006 5.2 - - -
Sievert, 
2011[50]
Unknown - -
Pregnant 
women
- 5.2 - - -
Pakistan
Sievert, 
2011[50]
Unknown 0 0
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These risk factors suggest that iatrogenic transmission 
is specifically found in Egypt[39,44,45,50,60,61], Iraq[44], 
Pakistan[40,50,53,57], Saudi Arabia[50], Sudan[44,45], Syria[50], 
and Yemen[44]. In Egypt, Pakistan, Saudi Arabia, Sudan, 
and Syria, factors associated with the community were 
also reported (contacts of HCV-infected patients, sharing 
razors, circumcision, injection from informal health 
provider, and tattooing, among others)[39,40,44,45,50,53,57,60,61]. 
Age[45,59,61], level of education in Yemen[44], intravenous 
drug use in Pakistan[57] and Syria[50], and homosexuality 
in Pakistan[57] were also associated with HCV infection.
DISCUSSION
Stretching from North Africa through the Middle East 
and into central Asia, the MENA region demonstrates 
a wide range of anti-HCV and viremic prevalences and 
diversity in HCV genotype distributions. For each country, 
our mapping of evidence gaps and quality assessment 
of outcomes reported on the available HCV morbidity 
measurements, their quality, and how well the SRs 
reported them and emphasized the opportunities for 
further population health research to better characterize 
HCV epidemiology in the region.
Quality assessment
Our overview of SRs identified that a substantial 
proportion of SRs on HCV epidemiology in MENA 
failed to report their outcomes following the PICOTS 
framework[25,26]. This can potentially lead to imprecise 
reported information that can, in turn, mislead data 
interpretation[26]. In addition to providing accurate 
information on HCV epidemiology, outcomes should 
also demonstrate practical and clinical significance and 
relevance. While most SRs of clinical research were 
determined to not be useful because their conclusions 
were false or exaggerated[66], it appears that we should 
also question the usefulness of SRs of population health 
research on HCV epidemiology in the MENA region. The 
SRs of HCV epidemiology in the MENA region stated that 
their aim was to provide a clear picture of the situation 
in the region. However, a substantial proportion of the 
Table 5  Hepatitis C antibody incidence and/or sero-conversion risk rate relative to the total sample size, and evidence gap mapping, 
Middle East and North Africa
Country Systematic review
Literature search 
period
Number 
of studies 
identified
Number of 
subjects Population type
Estimation 
time period
HCV incidence 
rate (per 1000 
person-year)
Loss of 
follow-up
HCV sero-
conversion risk 
(%)
Duration of 
follow-up
Iraq
Chemaitelly, 
2015[33]
1985-2015 1 57
Hemodialysis 
patients
2009 - 0 40.3 12 mo
Chemaitelly, 
2015[33]
1985-2015 1 123
Pediatric patients 
with acute 
lymphoblastic 
leukemia
2007 - 0 3.2
30 mo 
(median)
Chemaitelly, 
2015[33]
1985-2015 1 26
Newborn to HCV 
infected women
- - 0 0 6 mo
Chemaitelly, 
2015[33]
1985-2015 1 85
Pediatric cancer 
patients on 
chemotherapy
2006-2007 - 22 3.2 12 mo
Chemaitelly, 
2015[33]
1985-2015 1 60 Healthy children 2007-2009 - 0 0 6 mo
Chemaitelly, 
2015[33]
1985-2015 1 29
Pediatric patients 
with leukemia on 
chemotherapy
2007-2009 - 0 3.5 6 mo
Chemaitelly, 
2015[33]
1985-2015 1 27
Pediatric patients 
with leukemia 
who have had 
their baseline 
screening prior to 
chemotherapy
2007-2009 - 0 0 6 mo
Lebanon
Chemaitelly, 
2015[33]
1985-2015 0 0
Palestine
Chemaitelly, 
2015[33]
1985-2015 0 0
Jordan
Chemaitelly, 
2015[33]
1985-2015 1 1300
Hemodialysis 
patients
2003 - - 9.2 12 mo
Syria
Bashour, 
2016[91]
Unknown 0 0
Sievert, 
2011[50]
Unknown 0 0
United 
Arab 
Emirates
Mohamoud, 
2016[59]
Unknown 1 -
Hemodialysis 
patients
1995 108 - - -
Yemen
Chaabna, 
2016[27]
Inception-2015 0 0
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SRs in our overview lacked the key identified features of 
transparency (“are methods, data, and analyses verifiable 
and unbiased?”[66]) and pragmatism (“inferences should 
be applicable to real-life circumstances”[66]), which also 
are lacking in clinical research[66].
To reach the Global Health Sector Strategy on Viral 
Hepatitis (GHSS-VH) 2030 elimination goal[67], SRs 
of HCV epidemiology should assist policymakers in 
developing treatment programs and effective, precise 
prevention strategies for micro-elimination targeting 
specific populations at higher risk of acquiring HCV 
infections. Additionally, SRs of HCV epidemiology should 
guide changes to make clinical practices safer. Hence, an 
accurate picture is not obtainable by pooling population 
estimates of groups at different risk of acquiring HCV 
infections, such as patients undergoing hemodialysis 
combined with PWID, MSM combined with healthcare 
workers, or the GP combined with blood donors. 
Furthermore, estimated HCV outcomes should be as 
up-to-date as is reasonably possible, encompassing a 
narrow interval of time to attempt to depict the current 
situation in the region. The outcomes can be pooled 
by period, so potential changes in the epidemiological 
profile can be demonstrated. As such, dissemination of 
pooled estimates that combine data from many studies, 
some conducted two decades ago, in order to increase 
the statistical power does not appear to be useful in 
nowcasting the epidemiology of HCV in the region and 
is not helpful in developing effective preventive and 
treatment programs essential to attaining the 2030 HCV 
infection elimination goal. 
Conflict of interest
The evaluation of SRs should not be limited to the 
assessment of the reported methods, assumptions, 
data, and results[31]. Our overview emphasizes the 
significance of considering the disclosure of financial 
relationships while assessing research[31]. Researchers 
can be influenced by financial relationships while 
making judgments and decisions at a subconscious level 
such that they are not aware of the influence[31]. In the 
era of DAA treatment, the only published SRs providing 
the number of chronically HCV-infected individuals in 
the MENA region have substantial proportions of their 
authors who disclosed financial relationships with HCV 
DAA pharmaceutical companies. Our overview iden-
tifies a need in the MENA region for estimates of the 
number of chronically HCV-infected individuals who are 
candidates for DAA treatment by researchers who have 
not received financial assistance from Gilead Science.
Status of HCV epidemiology in the MENA region: 
Incidence
HCV infection is usually a slow progressive disease, 
which can lead to liver cirrhosis a couple of decades 
post-HCV infection[68]. Patients with liver cirrhosis are 
at 1%-5% annual risk of HCC and a 3%-6% annual 
risk of hepatic decompensation[68]. As such, a long 
period with non-specific symptoms passes before 
manifestations of HCV-related hepatic and extra-hepatic 
dysfunctions occur[69], which may then lead to the 
diagnosis of HCV infection. The distributions of these 
dysfunctions and diseases reflect past HCV infection 
transmission[69,70]. Hence, the prevalence of anti-HCV 
provides a retrospective snapshot of HCV transmission 
in a population, while the incidence describes the 
current HCV status in that population. Our overview 
also identifies research evidence gaps pertaining to up-
to-date anti-HCV incidence data in all MENA countries. 
Therefore, we recommend that additional research be 
conducted to measure the HCV incidence to assess 
current HCV transmission trends. Incidence studies 
in the GP and populations at differing levels of risk for 
acquiring HCV will allow real-time measurement of 
HCV transmission. Nowcasting will help policymakers to 
develop and implement efficient prevention strategies 
alongside treatment programs.
Status of HCV epidemiology in the MENA region: 
Prevalence in the general population
Among the 20 MENA countries, anti-HCV prevalence in 
the GP varied widely. Egypt, Pakistan, and Yemen were 
classified as having high prevalences of anti-HCV. In 
the six Gulf Nations, namely, Bahrain, Kuwait, Oman, 
Qatar, Saudi Arabia, and the UAE, the reporting quality 
of the anti-HCV prevalence data was poor (no data 
for Bahrain). Nevertheless, the available data in the 
GP demonstrate low-to-moderate prevalences of anti-
HCV in these countries. Remarkably, in these countries, 
the data from blood donors were of better reporting 
quality. Among blood donors, the anti-HCV prevalence 
was lower in nationals than in migrants, suggesting that 
the demographic characteristics of these Gulf Nations 
(nationals vs migrants) should be considered when 
describing the HCV epidemiology[71]. In these countries, 
population size increased rapidly in the last two decades 
due to the immigration of temporary workers[72]. More 
than 30% of the populations of the Gulf Nations are 
migrants; in Qatar and the UAE in 2014, this figure 
was over 80%[73,74]. In Qatar, Egyptian and Pakistani 
migrants accounted for 9% and 5% of the population, 
respectively, while Qatari nationals accounted for 12% 
(2016)[75]. HCV prevalence in a GP including both 
nationals and migrants in a country such as Qatar will 
be influenced by the HCV epidemiology profiles of the 
migrants’ countries of origin. Of note, migrants have 
to be negative for HIV, HBV, and HCV upon arrival in 
the Gulf Nations; however, screening is not mandatory 
thereafter, except for some professions such as those in 
the healthcare sector[76-81]. Thus, HCV-infected migrants 
in these countries would most likely have been infected 
while visiting their countries of origin.
Status of HCV epidemiology in MENA: Prevalence in 
blood donors
In countries that (1) prohibit persons at higher risk of 
acquiring blood-borne infection from donating blood and 
(2) systematically implement pre-transfusion screening 
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of blood donation for these infections, the prevalence of 
blood-borne infections in blood donors should be lower 
than that in the GP[28,29]. In some MENA countries, the 
anti-HCV prevalence was higher in blood donors than 
in the GP. Furthermore, in MENA countries, prevalence 
and incidence measurements in transfused patients 
and in patients with blood disorders suggest that HCV 
transmission in healthcare settings is prevalent and 
is likely to be ongoing. There is a need to ensure that 
patients receive the safest possible blood products. The 
management of all blood units and their components 
should guarantee that only those with negative HCV 
screening assays are sent to the hospitals to be used 
in transfusions. Strong regulatory policies for all blood 
banks must be implemented and enforced to achieve 
this.
Status of HCV epidemiology in the MENA region: 
Prevalence in healthcare settings
In Pakistan, HCV transmission due to unsafe injections 
(i.e., using contaminated needles and syringes) was 
identified in 2000[82], and in 2006, the proportion of 
people sharing injection equipment during their last 
injection was between 8.5% and 33.6%[83], suggesting 
that HCV transmission in healthcare settings was still 
ongoing. Additionally, we report that the prevalence of 
anti-HCV is higher in healthcare workers than in the 
GP in Iraq (2002-2010), Libya (1992-2004), Syria, 
and Yemen (study dates not reported). In 1999, HCV 
transmission in healthcare workers due to needle 
injuries from HCV-positive patients was reported in 
Pakistan[84]. The identified evidence suggests that 
occupational exposure to HCV occurs in healthcare 
settings in some MENA countries. In 2000, in order 
to prevent the transmission of HCV and other blood-
borne infections in healthcare settings, the World Health 
Organization recommended the implementation of 
strategies targeting healthcare workers and patients, 
focusing on achieving behavioral changes to reduce re-
use and over-use of injections, increase the exclusive 
use of sterile syringes and needles, and increase the 
proper disposal of sharp waste after use[85].
Status of HCV epidemiology in the MENA region: Key 
populations
Intravenous drug use appears to drive HCV infection 
in half the MENA countries, namely, Egypt, Lebanon, 
Libya, Morocco, Oman, Pakistan, Palestine, Saudi 
Arabia, Syria, and Tunisia. Relatively up-to-date data 
with good reporting quality were identified for these 
countries. However, missing data for the other MENA 
countries impact the evaluation of role of intravenous 
drug use in HCV transmission in a substantial part 
of the region. Prisoners are a key population rarely 
studied in MENA countries. We identified HCV outcomes 
in prisoners in only three countries (Libya, Iraq, and 
Lebanon). It appears that incarcerated individuals are 
at higher risk of acquiring HCV infections, especially 
HIV positive prisoners. Similarly, HCV epidemiology in 
MSM was described only in Sudan and Lebanon, and no 
data from HIV-infected MSM were identified. Lebanon, 
Libya, Sudan, Syria, and Tunisia reported higher anti-
HCV prevalences in female sex workers than in the 
GP, demonstrating that this population may be at 
higher risk of acquiring HCV infections. Consequently, 
population health research studies are needed in these 
key populations to comprehensively characterize HCV 
epidemiology in the MENA countries, which will facilitate 
better planning, development, and implementation of 
precise preventive strategies and treatment programs.
Status of HCV epidemiology in the MENA region: 
HBV and HIV co-infection, vertical transmission, and 
community
Co-infections with HCV and HBV or HIV, which share 
common modes of transmission, namely, through 
exposure to infected blood and sexual transmission[86], 
reminds us of the need for a holistic approach to tackle 
the population health issue of blood-borne infections. 
Additionally, the identified evidence regarding HCV 
morbidity (incidence and prevalence) in pregnant 
women and in children in Egypt, Pakistan, Saudi Arabia, 
and Yemen suggested that vertical HCV transmission 
may also occur. As for vertical transmission, little 
evidence was identified regarding community-acquired 
HCV infections. Additional research studies are needed 
to explore these transmission modes. 
Status of HCV epidemiology in the MENA region: 
Genotype geographical pattern
Genotype/subtype 1b is omnipresent across the region. 
Genotype 4 appears to be the most common in Egypt. 
In the Gulf Nations, the dominance of genotype 4 might 
be explained by the high proportion of migrants from 
Egypt. Genotype 3 is the most common in Pakistan, 
suggesting that intravenous drug use is likely the driver 
of HCV transmission in this country[87,88]. Genotype 3a in 
Pakistan appears to have emerged around the 1920s[88].
Many SRs reported HCV genotype/subtype distri-
butions and pooled frequencies without specifying the 
temporality of their identified geographical pattern. HCV 
genotypes differ according to the mode of transmission. 
For instance, while HCV-1b is the most prevalent HCV 
genotype/subtype globally[6], HCV-3 and 1a are linked to 
PWID, and in Asia, HCV-1a is also linked to PWID[87]. A 
birth cohort analysis demonstrated that the distribution 
of HCV genotypes is changing in Japan and appears to 
be associated with the establishment of the prevention 
of HCV transmission through blood transfusions or 
nosocomial infections in 1990[89]. In Japan, genotype 
1b is associated with the former mode of transmission, 
while genotypes 2a and 2b are associated with the latter 
mode of transmission[89]. Unfortunately, because of how 
genotype/subtype data are pooled and reported for the 
MENA region, we were not able to identify differences in 
time trends and geographic patterns.
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Quality assessment, strengths and limitations of our 
overview
We followed PRISMA guidelines[11-13] in reporting our 
work. All PRISMA required items regarding the abstract 
and the different sections of the main text were 
reported. Furthermore, we assessed our methodology 
using the AMSTAR tool[14]. We answered eight of the 11 
questions of this tool in the affirmative and reported the 
pages where the information can be found. The three 
remaining questions were not applicable to our work 
(e.g., “Were the methods used to combine the findings 
of studies appropriate[14]? Was not applicable because 
we did not conduct a meta-analysis).
The quality assessment of SRs we conducted was 
limited to all SRs of HCV epidemiology in the MENA 
region that were published in peer-reviewed journals 
indexed on Medline as identified through PubMed, which 
may not be representative of SRs of HCV epidemiology 
in the MENA region in general. However, PubMed has 
been recognized as the first public digital archive; as 
such, we can assume that we have assessed the quality 
of the majority of SRs of HCV epidemiology published 
in peer-reviewed journals[90]. Additionally, we critically 
synthesized all available data on HCV morbidity and risk 
factors reported by those SRs. Knowing that most of 
the 37 SRs included in our overviews conducted a multi-
source literature search including, in some SRs, a search 
for gray literature, we assumed that our synthesis in 
this overview is comprehensive. However, we might 
have missed some studies published recently that were 
not included in the SRs included in our overview. For 
instance, in Egypt, anti-HCV prevalence was estimated 
to be 6% in 2014[5], yet none of the SRs we included 
reported that estimate.
CONCLUSION
To reach the 2030 HCV infection elimination goal set by 
the GHSS-VH[67], evidence-based health policies need to 
be developed and implemented to optimize the allocation 
of financial resources and to alleviate the burden of 
disease due to HCV infection. Correct measures of anti-
HCV prevalence, viremia, and genotype distribution 
are essential for developing strategies to manage and 
eliminate HCV infection. Evidence gap mapping and 
quality assessment, along with reviewing reported 
conflicts of interest, revealed countries and specific 
populations where data are scarce and/or lacking in 
quality. We identified areas of opportunity to further 
develop population health research to comprehensively 
characterize HCV infection in the MENA region. Currently, 
the available estimates of the numbers of chronically 
HCV-infected patients who are candidates for the 
new DAA regimens are computed by researchers, a 
substantial proportion of whom have indirect or direct 
financial relationships with HCV DAA pharmaceutical 
companies. Additionally, a substantial proportion of the 
included SRs did not report precise outcomes, which 
can lead to misinterpretation of the data. Evidence-
based policies should be established from up-to-date 
information generated from rigorously designed studies 
and reported outcomes. 
Our synthesis of the published SRs of HCV epide-
miology in the MENA region demonstrates that despite 
the region being recognized as having the greatest 
HCV burden, a majority of the 20 countries have 
low to moderate anti-HCV prevalence. Only Egypt, 
Pakistan, and Yemen demonstrated a high anti-HCV 
prevalence. Iatrogenic transmission of HCV in patients 
and occupational exposure in healthcare workers are 
likely to be ongoing in the MENA countries. There 
is an urgent need for safer blood products and the 
implementation of safe medical practice guidelines. 
Intravenous drug use appears to be another common 
mode of HCV transmission in half the MENA countries. 
Research studies are needed to characterize the status 
of HCV epidemiology in PWID in countries where data 
are lacking. To develop effective prevention strategies 
and treatment programs to achieve HCV elimination, 
characterizing HCV epidemiology in key populations 
such as MSM and sex workers is essential and cannot be 
overlooked.
ARTICLE HIGHLIGHTS  
Research background
The Middle East and North Africa (MENA) has been identified as the region 
most affected by hepatitis C virus (HCV) infection worldwide predominantly due 
to the high HCV infection burden in Egypt and Pakistan. Since 2013, chronic 
infections with HCV genotypes 1, 2, 3, and 4 are curable, making elimination of 
HCV infection achievable for the first time. However, access and availability of 
the new direct-acting antiviral drug (DAA) regimens remains a challenge owing 
to country-level economic matters. 
Research motivation
Developing and prioritizing evidence-based strategies for prevention programs 
and treatment scale-up require up-to-date information generated from rigorously 
designed studies and reported outcomes. A substantial number of systematic 
reviews of HCV infection in the MENA region have been published. What is 
the quality of these systematic reviews and what is the quality of the studies 
included in these systematic reviews? Researchers can be influenced by 
financial relationships while making judgments and decisions at a subconscious 
level such that they are not aware of the influence. The use and interpretation 
of the outcomes in the systematic reviews need to be viewed keeping in mind 
the reported conflict of interests by the authors of the systematic reviews. Our 
overview was also motivated because of the following questions: what do we 
know about hepatitis C epidemiology in the MENA region? High country-level 
anti-HCV prevalence has been identified in Egypt and Pakistan. What is the 
status of the other 18 MENA countries? What are the identified potential modes 
of transmission and populations at higher risk of acquiring hepatitis C infection?
Research objectives
The primary objective of our overview is to assess the quality of the data 
reported by the published systematic reviews of HCV epidemiology in the 
MENA countries taking into account conflict of interest disclosed by the 
authors of these systematic reviews. Our secondary objective is to produce a 
comprehensive picture of HCV infection epidemiology in the 20 countries of the 
MENA region.
Research methods
An a priori protocol of our overview is registered with the International 
Prospective Register of Systematic Reviews (PROSPERO registration number 
CRD42017076736). We conducted an overview of systematic reviews based 
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on the Cochrane Handbook for Systematic Reviews of Interventions. We 
used broad search criteria to include all systematic reviews on HCV infection 
in the MENA region published after 2008 - the publication year of the first 
version of the Cochrane Handbook for Systematic Reviews of Interventions. 
We extracted all relevant outcomes related to HCV infection epidemiology. 
The nine primary outcomes of interest were HCV antibody (anti-) prevalences 
and incidences in different at-risk populations; the HCV viremic (RNA positive) 
rate in HCV-positive individuals; HCV viremic prevalence in the general 
population; the prevalence of HCV co-infection with the hepatitis B virus, 
human immunodeficiency virus, or schistosomiasis; the HCV genotype/subtype 
distribution; and the risk factors for HCV transmission. Thereafter, we critically 
analyzed and synthesized the extracted data by assessing their quality - 
using PICOTS framework, by evaluating conflict of interests disclosed by the 
authors of the systematic reviews, and by mapping the evidence and the gaps. 
Our overview is reported following PRISMA guidelines and assessed using 
AMSTAR tool.
Research results
Data reporting in a substantial proportion of systematic reviews on HCV 
infection in MENA may mislead the interpretation of these data. Our overview 
identified that a substantial proportion of the systematic reviews failed to report 
their outcomes following the PICOTS framework. Additionally, a substantial 
proportion of the systematic reviews lacked the key identified features of 
transparency and pragmatism. Our overview emphasizes the significance of 
considering the disclosure of financial relationships while assessing research 
and its reported outcomes. In the era of DAA treatment, the only published 
systematic reviews providing the number of chronically HCV-infected individuals 
in the MENA region - number of candidates for DAA treatment, have a large 
number of authors who disclosed financial relationships with HCV DAA 
pharmaceutical companies. We identified low prevalence of anti-HCV (< 1.5%) 
in Djibouti, Kuwait, Oman, Qatar, and UAE; moderate prevalence (1.5%-3.5%) 
in Algeria, Iraq, Lebanon, Libya, Morocco, Saudi Arabia, Sudan, Syria, and 
Tunisia; and high prevalence (> 3.5%) in Egypt, Pakistan, and Yemen. In 
Pakistan, anti-HCV prevalence may have increased from 5.4% in 1996-2007 to 
6.7% in 2007-2008. No reported data in the general population was identified 
for Bahrain, Jordan, or Palestine. Intravenous drug use appears to drive HCV 
infection in Egypt, Lebanon, Libya, Morocco, Oman, Pakistan, Palestine, Saudi 
Arabia, Syria, and Tunisia. Relatively up-to-date data with good reporting quality 
were identified for these countries. However, missing data for the other ten 
MENA countries affect the evaluation of role of intravenous drug use in HCV 
transmission in a substantial part of the region. Furthermore, we identified that 
HCV transmission most likely occurs in healthcare settings due to iatrogenic 
and/or occupational exposures. Community-acquired HCV infection may 
also occur in the MENA countries; however, we identified evidence gaps in 
the region. Often, anti-HCV prevalence measures were not identified for key 
populations such as prisoners, men who have sex with men, and sex workers. 
Anti-HCV prevalence data were predominantly missing for the countries of the 
Gulf Cooperation Council and Yemen.
Research conclusions
Correct measures of anti-HCV prevalence, viremia, and genotype distribution 
are essential for developing strategies to manage and eliminate HCV infection. 
Evidence gap mapping and quality assessment, along with reviewing reported 
authors conflict of interest, revealed MENA countries and specific populations 
where data are scarce and/or lacking in quality. Our overview comprehensively 
characterizes hepatitis C epidemiology in the 20 countries of the MENA region 
and emphasizes their needs in terms of treatment and prevention. This will 
help policy makers of these countries to develop and prioritize evidence-based 
strategies for prevention programs and treatment scale-up in the region. This 
overview will contribute to the improvement of population health research 
practices in order to build research capacity in the MENA region
Research perspectives
Future systematic reviews on HCV epidemiology in the MENA region should 
strive to provide accurate information on HCV epidemiology demonstrating 
practical and clinical significance and relevance. To facilitate the development 
of precise prevention strategies and treatment programs, we recommend 
when estimating and reporting HCV prevalence and incidence, to avoid mixing 
populations at differing risk of acquiring HCV. Furthermore, up-to-date and good 
quality data are required in order to nowcast HCV epidemiology in the region. 
When data is available for long time periods, reporting should reflect changes 
in prevalence or incidence over time, which will allow to accurately describe the 
past and current HCV epidemiology in a population.
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